Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 adjuvant therapy after resection of hepatocellular carcinoma
2007-005011-25Phase 3Active
- Sponsor
- Progen Pharmaceuticals
- Start
- Dec 2007
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing PI-88 arm with Placebo arm (2 arms). Primary endpoint: Disease-free survival. Started Dec 2007; status: active.
02
Drugs
Muparfostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2007-005011-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005011-25.